Tag: turn
Agios’ Tibsovo has an FDA green light in AML. Why did...
Agios may have persuaded the FDA into doling out an approval for its acute myeloid leukemia (AML) drug Tibsovo based on phase 1 results,...
Where can Biogen turn after mammoth Alzheimer’s blow? The M&A table,...
Biogen investors’ worst fears have come true with the failure of its phase 3 Alzheimer’s prospect, and now, it may be “buy or be...
